Every mechanism on this page is a proposal from laboratory and animal work. None is confirmed in humans. Even the plant’s best human result, the dry-eye trial, has an open mechanism, because the follow-up study designed to confirm it found the opposite of what the theory predicted.
The mucosal membrane hypothesis
The most quoted mechanism runs like this: berry oil is rich in palmitoleic acid, the omega-7 fatty acid, mucosal membranes in the eye, vagina, and gut share biology, so the oil should nourish those surfaces. Human trials did find benefits for dry eyes and vaginal dryness. Then the 2011 follow-up measured tear-film fatty acids in the dry-eye cohort and found no difference between the oil and placebo groups. The benefit is real and the proposed pathway is unconfirmed, which is exactly how open mechanisms should be reported. The dry-eye trial page dissects both studies.
The 2011 study deserves its reputation as this site’s favorite null. The team that ran it had published the benefit, believed the pathway, and held the samples that could prove it. Their measurement came back flat: the oil’s fatty acids never appeared in the tear film. Whatever the oil does for dry eyes, it does not do it by shipping palmitoleic acid to the surface of the eye. The current candidates, signaling effects or systemic anti-inflammatory action, are proposals until someone designs the experiment that tells them apart.
The antioxidant frame
The oil carries tocopherols and carotenoids, the berries carry vitamin C, and composition studies confirm the cargo. A 2024 trial added a blood data point: 1 gram of oil daily for 12 weeks raised the antioxidant enzyme catalase by 82.8 percent in 40 women. That is a real measurement of antioxidant activity in human blood, and it still does not prove disease prevention, because antioxidant chemistry has a long history of failing to predict health outcomes. The antioxidants glossary defines the terms.
The caution is not abstract. Large trials of isolated antioxidant vitamins spent decades failing to prevent the diseases their chemistry predicted, which is why one enzyme moving in one small trial stays exactly that: one enzyme, one small trial. The carotenoids glossary and the tocopherols glossary hold the compound-by-compound versions.
The lipid-handling hypothesis
Two mechanisms could plausibly move cholesterol numbers: phytosterols in the berry oil competing with cholesterol for absorption, and the oil’s unusual fatty acid pattern, measured across cultivars in the composition literature. The Geng 2022 meta-analysis confirmed that lipids move in people with abnormal levels, detailed on the cholesterol meta-analysis page, but no trial has isolated which compound class does the work. The omega-7 research page shows what happens when marketers splice the lipid result onto isolated omega-7 without a trial.
The two candidates also predict different things, which is how a future trial could tell them apart: phytosterol competition acts in the gut and should move cholesterol regardless of the oil’s fatty acid pattern, while a fatty-acid mechanism should track the specific profile of the oil dosed. Nobody has run that comparison. Until someone does, both stay in the proposal column, and the lipid result stays credited to the oil as a whole.
The flavonoid pathways
Cell studies show the berry’s flavonoids, quercetin, kaempferol, and isorhamnetin, touching inflammation signaling pathways. The same 2024 trial found the inflammatory signal TNF-alpha down 23 percent in human blood. Cell pathways at lab concentrations are notoriously poor predictors of effects at food-level blood levels, so these remain proposed mechanisms with one small human marker study behind them. The flavonoids glossary maps the family, and the grading rule stays the same throughout: a pathway touched in a dish is a pathway proposed, never a pathway proven.
The mechanism claims to refuse on sight
Three mechanism stories get sold far past their evidence. The fat-burning omega-7 story comes from mouse metabolism studies, and mouse findings in this area fail to translate to people more often than they translate. The estrogen-mimic story for menopause is contradicted by the vaginal trial’s own measurements, which found no estrogenic effect on the markers it tracked. And the immune-boost story survived exactly one human test, the berry trial that found no effect on colds. Each is a mechanism built to explain a benefit that was never demonstrated in people in the first place.
What would move a proposal to proof
The path is the same for every candidate on this page: design a human trial where the proposed mediator is measured alongside the outcome, and where varying the mediator changes the result. The dry-eye follow-up was exactly that design, which is why its null taught so much. Until a pathway survives that test, it belongs to the reading-studies page category of interesting context, not to any product claim. The safety review shows the mirror image: the one mechanism with direct human measurement, platelet aggregation, is the one that drives a practical rule.
How to hold mechanism claims
A mechanism plus a confirming human outcome trial is strong science. A mechanism alone is a hypothesis with good PR. Every grade on this site counts human outcomes first and treats mechanisms as supporting argument, which is why the clinical trials catalog is the spine and this page is the footnote. That ordering protects you in both directions: it keeps a promising pathway from becoming a claim, and it keeps a confirmed claim from needing its pathway to stay valid. The consumer cholesterol page shows how the framing survives translation, and the research hub holds the grading scale.
Frequently asked questions
How does sea buckthorn work in the body?
Honestly, the mechanisms are proposed rather than confirmed. Lab and animal work supports several candidates: fatty acids interacting with mucosal membranes, tocopherol and carotenoid antioxidant chemistry, phytosterol competition with cholesterol absorption, and flavonoid signaling. Even the best human result, the dry-eye trial, has an open mechanism, because the follow-up study found tear-film fatty acids unchanged.
Do we know how sea buckthorn works?
Partially, and every honest answer names the level. One mechanism has direct human measurement, the platelet effect. One has a human outcome with an unexplained pathway, dry-eye relief. The rest are proposals from lab and animal chemistry: mucosal fatty acids, antioxidant enzymes, phytosterol competition, flavonoid signaling. A proposal is not a guess to be ashamed of. It is a question with data behind it, waiting for the experiment that proves or refutes it.